| First Author | Shapiro MR | Year | 2020 |
| Journal | Front Immunol | Volume | 11 |
| Pages | 2180 | PubMed ID | 33013915 |
| Mgi Jnum | J:308231 | Mgi Id | MGI:6727665 |
| Doi | 10.3389/fimmu.2020.02180 | Citation | Shapiro MR, et al. (2020) CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation. Front Immunol 11:2180 |
| abstractText | The costimulatory molecule CD226 is highly expressed on effector/memory T cells and natural killer cells. Costimulatory signals received by T cells can impact both central and peripheral tolerance mechanisms. Genetic polymorphisms in CD226 have been associated with susceptibility to type 1 diabetes and other autoimmune diseases. We hypothesized that genetic deletion of Cd226 in the non-obese diabetic (NOD) mouse would impact type 1 diabetes incidence by altering T cell activation. CD226 knockout (KO) NOD mice displayed decreased disease incidence and insulitis in comparison to wild-type (WT) controls. Although female CD226 KO mice had similar levels of sialoadenitis as WT controls, male CD226 KO mice showed protection from dacryoadenitis. Moreover, CD226 KO T cells were less capable of adoptively transferring disease compared to WT NOD T cells. Of note, CD226 KO mice demonstrated increased CD8(+) single positive (SP) thymocytes, leading to increased numbers of CD8(+) T cells in the spleen. Decreased percentages of memory CD8(+)CD44(+)CD62L(-) T cells were observed in the pancreatic lymph nodes of CD226 KO mice. Intriguingly, CD8(+) T cells in CD226 KO mice showed decreased islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-tetramer and CD5 staining, suggesting reduced T cell receptor affinity for this immunodominant antigen. These data support an important role for CD226 in type 1 diabetes development by modulating thymic T cell selection as well as impacting peripheral memory/effector CD8(+) T cell activation and function. |
